Safety, Tolerability and Pharmacokinetics Study of CK-3773274
A Phase 1, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of CK-3773274 in Healthy Chinese Subjects
Sponsor: Corxel Pharmaceuticals
Listed as NCT04783766, this PHASE1 trial focuses on Healthy Adult Subjects and Obstructive Hypertrophic Cardiomyopathy and remains completed. Sponsored by Corxel Pharmaceuticals, it has been updated 7 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Feb 2025 — Present [monthly]
Completed PHASE1
-
Jan 2025 — Feb 2025 [monthly]
Completed PHASE1
-
Sep 2024 — Jan 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
▶ Show 2 earlier versions
-
May 2021 — Oct 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Apr 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Corxel Pharmaceuticals
- Cytokinetics
For direct contact, visit the study record on ClinicalTrials.gov .